EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients

E Silkenstedt, M Dreyling

Hematological Oncology · 2025

DOI: 10.1002/hon.70073 ↗

At a glance

Übersichtsarbeit in Hematological Oncology, 2025. Written by E Silkenstedt and 1 co-authors. Institution: Department of Medicine III, LMU Hospital, Munich, Germany. Major MEDLINE topics: Lymphoma, Mantle-Cell, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Agammaglobulinaemia Tyrosine Kinase. Cited 1 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The development and implementation of new targeted and immunotherapeutic approaches in the treatment landscape of mantle cell lymphoma have already improved therapeutic options especially for refractory or relapsed disease. Regarding first‐line therapy, treatment strategies including novel agents are under investigation. In transplant‐eligible patients, a combined ibrutinib‐containing immunochemotherapy induction followed by ASCT was shown to be superior compared to the chemotherapy regimen +/− ASCT. Thus, we consider the addition of ibrutinib to first‐line therapy in younger MCL patients a new standard of care. For the group of older MCL patients ineligible for high‐dose therapy and ASCT, several targeted therapy approaches have been investigated in different studies in combination with immunochemotherapies or as single agents +/− other targeted therapies with promising results. This review summarizes the current standard of care for first‐line treatment of mantle cell lymphoma, highlighting the implementation of targeted treatment strategies, especially BTKi, in initial treatment strategies. Trial Registration: ClinicalTrials.gov identifier: NCT06482684

Subjects

MeSH terms (MEDLINE)

Lymphoma, Mantle-CellProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAgammaglobulinaemia Tyrosine KinaseHumansPiperidinesAdenine

Author keywords

BTKiMCLfirst line

Substances

Protein Kinase InhibitorsPiperidinesAgammaglobulinaemia Tyrosine KinaseAdenine

Authors and institutions

  • Department of Medicine III, LMU Hospital, Munich, Germany.

Cite

APA

Silkenstedt, E., & Dreyling, M. (2025). First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients. Hematological Oncology. https://doi.org/10.1002/hon.70073

Vancouver

Silkenstedt E, Dreyling M. First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients. Hematological Oncology. 2025. doi:10.1002/hon.70073

BibTeX
@article{Silkenstedt2025,
  author = {Silkenstedt, E and Dreyling, M},
  title = {First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70073}
}
Start for free →